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Abstract
Caspase-2 was discovered almost three decades ago. It was one of the first two mammalian homologs of CED-3, the
other being interleukin 1β-converting enzyme (ICE/caspase-1). Despite high similarity with CED-3 and its fly and
mammalian counterparts (DRONC and caspase-9, respectively), the function of caspase-2 in apoptosis has remained
enigmatic. A number of recent studies suggest that caspase-2 plays an important role in the regulation of p53 in
response to cellular stress and DNA damage to prevent the proliferation and accumulation of damaged or aberrant
cells. Here, we review these recent observations and their implications in caspase-2-mediated cellular death,
senescence, and tumor suppression.
Introduction
Cysteine aspartate-specific proteases (caspases) are key
drivers of inflammation and cell death. They mediate the
processing and activation of proinflammatory cytokines
or cleave several proteins during apoptosis to facilitate the
programmed disassembly of cells1,2. Caspases also func-
tion in other pathways, including cell proliferation and
differentiation. In general, caspases can be functionally
split into two main groups. For example, mammalian
caspase-2, -3, -6, -7, -8, -9, and -10 are apoptotic caspases,
whereas caspase-1, -4, -5, -11, and -12 are involved in
inflammation (or inflammation-induced cell death)1,2. In
contrast to the other caspases, caspase-14 is mostly
expressed and activated in the differentiating and corni-
fying layers of the epidermis and plays a crucial role in
epidermal barrier formation2. The caspases implicated in
apoptotic cell death can be further divided into initiators
and effectors. As the term implies, initiator caspases are
activated first in response to apoptotic signals, and once
activated, they mediate the activation of effector caspases
through proteolytic cleavage events. Effector caspases
then cleave several hundred potential targets in the cell
undergoing apoptotic dismantling. Initiator caspases are
autoactivated2,3. They contain long prodomains near the
N-terminus that comprise either death effector domains
(DEDs; caspase-8 and -10) or caspase-recruitment
domains (CARDs; caspase-2, -9, -1, and -11)2,4. These
domains mediate protein dimerization and/or recruit-
ment into larger complexes, such as apoptosomes5 and
death-inducing signaling complexes (DISCs), to facilitate
their activation6. The main effector caspases, caspases-3
and -7, do not possess the ability to autoactivate and their
processing must be induced by initiator caspases2.
Apoptotic caspase activation occurs via two main path-
ways. The mitochondrial pathway (BCL-2-regulated or the
intrinsic pathway) is activated in response to various forms
of cellular stress, including DNA damage, whereas the
tumor necrosis factor (TNF) family of ligands initiates the
alternative (extrinsic) pathway of apoptosis by binding to
their cognate receptors (Fig. 1)1,3,6. The mitochondrial
pathway involves the proapoptotic BCL-2 family members
BAX and BAK7, which induce mitochondrial outer
membrane permeabilization (MOMP)8,9 and promote
cytochrome c release. The apoptotic protease-activating
factor-1 (APAF-1) associates with cytochrome c in a
multimeric apoptosome to activate caspase-95. In the
extrinsic pathway, apoptosis signaling via TNF family
members is initiated following ligand-dependent activation
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of TNF family death receptors (such as FAS, TNFR,
TRAILR1, and TRAILR2)6. The cytoplasmic domains of
active multimeric receptors recruit and activate caspase-8
or -10 via DISC, which consists of FAS-associated death
domain protein (FADD) and/or TNFR-associated death
domain protein (TRADD), as well as other proteins (e.g.,
TRAFs and RIP1) that modulate death receptor signal-
ing10. Activated caspase-8 can activate caspase-3 and
caspase-711 and cleave BID to a truncated form (tBID),
which engages the mitochondrial pathway to amplify the
apoptotic response through MOMP12 (Fig. 1).
The focus of this review is caspase-2, a CARD-containing
caspase. It is the most evolutionarily conserved member of
the caspase family, with 31% identity (55% similarity) with
the C. elegans caspase CED-3 and 25% identity (40%
similarity) with the only Drosophila initiator caspase:
DRONC13–15. Caspase-2 is expressed in almost all
metazoan cells and is rapidly processed in response to
various intrinsic and extrinsic apoptotic signals3,13,16–23.
Similar to other initiator caspases, caspase-2 activation
occurs via CARD-mediated homodimerization and
autoprocessing24–27 (Fig. 2). Caspase-2 is also recruited to a
large multiprotein complex called the PIDDosome28 (see
below). Caspase-2 is the only caspase with a classical
nuclear localization signal that mediates its predominant
localization to the nucleus29. While caspase-2 is implicated
in many cell death and non-cell death functions30, here, we
discuss recent data that link caspase-2 to p53 stability and
Fig. 1 Conserved apoptotic pathways. Core apoptotic machinery in C. elegans and in mammals that drives caspase activation is shown. In
mammals, there are two main apoptosis pathways. In the intrinsic pathway, various cellular insults result in MOMP and cytochrome c release from
mitochondria, which drives apoptosome-dependent caspase-3 activation. In the extrinsic pathway, TNF family members activate caspase-8 via DISC.
Activated caspase-8 and caspase-9 mediate the processing and activation of effector caspases, of which caspase-3 is the most prominent. The figure
was created with BioRender.com.
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Fig. 2 Caspase-2 structure and activation. In the primary structure, the location of zymogen cleavage sites, CARD, p19, p12, nuclear localization
signal (NLS), and the catalytic Cys residue are shown. The putative ubiquitination and phosphorylation sites are also indicated. Various biochemical
steps that lead to mature dimeric caspase-2 are shown. A ribbon diagram displays the dimeric structure of caspase-2 with two substrate binding
pockets, including catalytic Cys (PDB ID: 3R6G)32. The figure was created with BioRender.com.
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its various functions, including cell cycle regulation and
tumor suppression.
Caspase-2 activation
Through its CARD, overexpressed caspase-2 can rapidly
oligomerize, which is sufficient for its activation24,26,29.
Caspase-2, a zymogen with basal enzyme activity that is
promoted by dimerization, is further activated by its pro-
teolytic processing into two subunits, p19 and p1231 (Fig. 2).
Structural studies suggest that mature caspase-2 forms a
p19/p12 homodimer in solution with two active sites32.
Biochemical data suggest that caspase-2 can be initially
activated without processing and without other proteins24;
however, in cell extracts, caspase-2 is recruited to a large
complex, which probably mediates its full activation in
response to various signals25. One such activation complex
is the PIDDosome, which comprises PIDD1 (p53-induced
death domain-containing protein 1), RAIDD (RIP-asso-
ciated ICH-1/CED-3 homologous proteins with a death
domain), and caspase-233,34. The PIDDosome is considered
to be the main signaling platform for caspase-2 activation in
response to DNA damage35,36 and cytokinesis failure37.
Somewhat surprisingly, however, PIDD1- or RAIDD-
deficient cells and mice show normal caspase-2 activa-
tion38–40. Caspase-2 can also be activated in response to
bacterial toxins in a PIDDosome-independent manner41.
The serine/threonine kinase ATM (ataxia telangiectasia
mutated) has been shown to directly promote PIDDo-
some formation induced by DNA damage35,38,39. ATM
phosphorylates Thr788 in the death domain (DD) of
PIDD1, leading to conformational changes and allowing
binding with RAIDD through DD interactions35,42. More
recently, the phosphoprotein nucleophosmin (NPM1) has
been shown to control PIDDosome formation specifically
in the nucleolus, which activates caspase-2 in response to
DNA damage43. The authors also demonstrated a
RAIDD-dependent, but PIDD1-independent, platform for
caspase-2 activation in the cytoplasm, while both RAIDD
and PIDD1 are involved in a nucleolar platform43.
Although many studies have demonstrated the physio-
logical importance of PIDDosome complex as a caspase-2
activation platform, other potential mechanisms of
caspase-2 activation have also been reported. As men-
tioned above, caspase-2 was also shown to be activated in
DISC, which includes CD95 (FAS/APO-1) and
TNFR144,45. Recently, NLRP3 has also been proposed to
be a possible caspase-2 activation platform46. In this
study, NLRP3 was translocated to mitochondria upon ER
stress, leading to caspase-2 activation following the release
of mitochondrial DNA and cytochrome c, resulting in
inflammasome activation46. In addition, TRAF2 was
shown to promote caspase-2 activation in a complex
following cisplatin treatment of cells47. PIDD1 and
RAIDD were not essential in this context47.
Caspase-2 activity can be regulated by several factors,
including its localization, transcription and posttranslational
modifications, including phosphorylation and ubiquitina-
tion47,48. A recent study reported that caspase-2 ubiquiti-
nation is required to stabilize caspase-2 dimerization and
activation in a TRAF2-dependent manner in cultured
cells47. Specifically, caspase-2 dimerization and further
activation upon cisplatin treatment involved TRAF2-
mediated ubiquitination at Lys15, Lys152, and Lys15347.
To date, several phosphorylation sites have been found to
be important for caspase-2 regulation in certain contexts.
Under nutrient-replete conditions that satisfy the pentose
phosphate pathway in Xenopus oocytes, Ser135 (Ser164 in
humans) of caspase-2 is phosphorylated by calcium/cal-
modulin-dependent kinase II (CAMKII), resulting in inhi-
bition of caspase-2 activation49. Caspase-2 activation is also
inhibited by phosphorylation at Ser157 by the protein
kinase casein kinase-2 (CK2) in TNF-alpha-related
apoptosis-inducing ligand (TRAIL)-mediated apoptosis50.
A recent study showed that phosphorylation at Thr180 of
caspase-2 is p38 mitogen-activated protein kinase (MAPK)-
dependent and important in sterol regulatory element-
binding protein 2 (SREBP2) regulation in lipid metabo-
lism51. It is unclear whether p38 MAPK phosphorylates
Thr180 directly. In the context of the cell cycle and DNA
damage response, phosphorylation-dependent control of
caspase-2 activity may be most relevant. For example,
CDK1-Cyclin B1-dependent phosphorylation at Ser340
inhibits caspase-2 to protect cells from incidental apoptotic
death during mitosis52. Recent data indicate that a key
mitotic kinase, Aurora kinase B (AURKB), phosphorylates
caspase-2 at the highly conserved residue Ser38453. A
phosphomimetic mutation at Ser384 blocks caspase-2 cat-
alytic activity, preventing the cleavage of its substrates, BID
and MDM2, in cells with mitotic errors. Structural analysis
suggests that phosphorylation at Ser384 may prevent sub-
strate binding53. Therefore, phosphorylation prevents clea-
vage of the key caspase-2 substrates involved in apoptosis
and p53 stabilization (see below).
Caspase-2 – cell cycle connection
Possible links between caspase-2, p53 and the cell cycle
have been consistently reported. For example, caspase-2-
deficient murine embryonic fibroblasts (MEFs) proliferate
faster and become immortalized quicker than their wild-
type counterparts54,55. Caspase-2 has been shown to
interact with cyclin D3, which regulates the G1/S transi-
tion during the cell cycle56. Furthermore, as stated above,
caspase-2 can be phosphorylated by CDK1-Cyclin B1, a
mitosis-promoting kinase, during mitosis52. This phos-
phorylation inhibits caspase-2 activation, preventing
unwanted cell death during mitosis. A role for caspase-2
in mitotic catastrophe was proposed approximately 15
years ago57. Mitotic catastrophe is programmed cell death
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resulting from failed mitosis, including delayed mitosis
and failure to repair DNA damaged by physical or che-
mical stresses1,58. CHK2 inhibition was shown to induce
mitotic catastrophe and caspase-2-dependent cell death,
and the inhibition/ablation of caspase-2 suppresses
mitotic catastrophe, resulting in multinucleated and
aneuploid cells57. Later, Sidi and colleagues showed that
inhibition of CHK1, a cell cycle regulating kinase, causes
ATM/ATR-mediated caspase-2 activation and results in
nonapoptotic cell death program initiation, even in p53-
deficient cells59. These reports suggest that inhibition of
either CHK1 or CHK2 results in mitotic catastrophe
involving caspase-2-mediated cell death.
Ongoing errors in chromosome segregation caused by
dysfunctional cell cycle checkpoints, such as spindle
assembly checkpoints (SACs) or cytokinesis failure during
mitosis, can cause aneuploidy, which often leads to
chromosomal instability (CIN), a hallmark of cancer60.
This failure is often associated with defects in the acti-
vation of apoptotic pathways. For example, mutation of
the p53 tumor suppressor or overexpression of the pro-
survival BCL-2 family of proteins are common precursors
to malignant transformation and therapy resistance61,62.
Caspase-2 deficiency is closely associated with enhanced
aneuploidy in primary MEFs and tumors13,54,63–65.
Similarly, bone marrow cells from aged but not young
caspase-2-deficient mice also showed significantly higher
aneuploidy than bone marrow cells from WT mice66.
Recent studies showed that increased aneuploidy in
caspase-2-deficient and caspase-2-catalytic mutant mouse
cells reduced BID cleavage and cell death and clonogenic
survival following polo-like kinase 1 (PLK1) inhibition in
caspase-2-deficient cells (Fig. 3a, d)67. This finding implies
a requirement for the enzymatic activity of caspase-2 in the
apoptosis of aneuploid cells; however, it is unknown
whether the PIDDosome is essential.
BUBR1 is a core protein of the mitotic checkpoint
complex in mitosis control, and it has been shown to be
an inhibitor of the PIDDosome in response to irradiation-
mediated DNA damage36. Specifically, following DNA
damage during mitosis, BUBR1 recruits ATM phos-
phorylated PIDD1 to the kinetochore, outcompeting
RAIDD for PIDD1 binding, thus preventing PIDDosome
formation. This mechanism helps prevent unplanned cell
death during cell division and implicates the PIDDosome
and caspase-2 as critical mitosis regulators36.
Caspase-2 stabilizes p53 following DNA damage
In addition to the findings discussed above, caspase-2
deficiency has often been linked to a defective DNA
damage response. For example, caspase-2-deficient MEFs
readily escape senescence in culture and exhibit increased
micronuclei formation and sustained DNA damage dur-
ing cell culture and following γ-irradiation54. A lack of
caspase-2 is known to be associated with increased
aneuploidy in both MEFs and in EμMyc lymphoma cells,
and loss of caspase-2 leads to defective p53-mediated
signaling, suggesting that caspase-2 is important in
maintaining genomic integrity during cell proliferation
and following DNA damage54,55. Other studies have
implicated both PIDD1 and caspase-2 in DNA damage-
dependent p53-mediated apoptosis68,69. Recent observa-
tions indicate that active caspase-2 stabilizes p53, result-
ing in cell cycle arrest and/or apoptosis (Fig. 3). The levels
of p53 are regulated by the ubiquitin ligase MDM2, which
is critical for the ubiquitination and degradation of p5370–72.
In a seminal study published in 2011, Oliver and collea-
gues found that caspase-2 directly cleaves MDM2 at
Asp367, resulting in the removal of the C-terminal RING
domain that is critical for p53 ubiquitination68. N-
terminally truncated MDM2 then binds p53 and pro-
motes its stability68. Thus, this finding suggested for the
first time that, following genotoxic stress and DNA
damage, p53-dependent induction of the PIDDosome and
caspase-2 activation generates a positive feedback loop
that inactivates MDM2 and promotes p53 stability.
As MDM2 is also a transcriptional target of p53,
increased p53 levels drive MDM2 expression, which in turn
results in p53 degradation via the ubiquitin-proteasome
system73,74. Thus, an MDM2-p53 negative feedback loop
results in oscillatory p53 pulses following double-stand
DNA breaks and ATM activation75–77. On the other hand,
in response to UV-induced DNA damage that activates
ATR, p53 is expressed as a broad pulse78. A study published
in 2020 suggests that several days after ionizing radiation-
induced DNA damage, some cells switch from oscillating to
sustained p53 dynamics79. Using a Venus fluorescent
reporter to monitor p53 levels in single cells, the authors
found that following 10Gy irradiation, 15–20% of cells
exhibit stably increased p53 levels79. Interestingly, the
fraction of cells switching from pulsatile to sustained p53
levels was maximal at 5 Gy but reduced with increasing
radiation dose of 10 or 20Gy dose. The cells with sustained
p53 signaling showed chromosomal damage. The authors
found that late phase p53 levels were reduced in irradiated
PIDD1-deficient cells and in cells following caspase-2
inhibition79. Overall, their data suggest that PIDD1 and
caspase-2 are required for cells that evade DNA damage-
induced cell cycle arrest to switch from pulsating to sus-
tained p53 signaling. Thus, the presence of damaged DNA
activates caspase-2 via the PIDDosome to stabilize
p53 signaling and thus limits the proliferation of cells car-
rying extensive DNA damage by inducing apoptosis (Fig. 4).
Caspase-2 in ploidy control
A study by Fava and coworkers demonstrated that extra
centrosomes resulting from cytokinesis failure trigger
PIDDosome-dependent caspase-2 activation37. Activated
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caspase-2 then cleaves MDM2, leading to p53 stabilization
and p21-mediated cell cycle arrest of polyploid cells
(Fig. 3a–c). The study showed that PIDD1 can localize to
extra mother centrioles and that caspase-2 activation
following AURKB inhibition is dependent on PIDD1 and
RAIDD37. Importantly, the PIDDosome was essential for
caspase-2 activation in this context and was required to
protect cells against polyploidization and malignant
Fig. 3 Caspase-2 functions in cell cycle arrest and apoptosis. a Schematic showing that the cell cycle arrest and apoptotic functions of caspase
are mediated via cleavage of MDM2 and BID following mitotic catastrophe, respectively. Figure created with BioRender.com. b An example of MDM2
cleavage by caspase-2 (Casp2) following treatment of WT or caspase-2-deficient (KO) U2OS cells with or without the AURKB inhibitor ZM447439 (ZM).
c Panels showing examples of increased multinucleated (arrow) caspase-2-deficient U2OS cells following AURKB inhibition. Scale bar, 50 µm.
d Examples of caspase-2-mediated BID cleavage (appearance of truncated BID, tBID) following treatment with a PLK1 inhibitor, BI2536 (BI), which
induces mitotic arrest. fl.; full-length, cl.; cleaved, p33 and p18; cleaved caspase-2. The data and images in b–d were generated by Yoon Lim.
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transformation37. A more recent study showed p53
stabilization and effective cell cycle arrest following treat-
ment with the same AURKB inhibitors in caspase-2-
deficient U2OS cells80, suggesting that caspase-2-mediated
p53 stabilization may be cell-type specific. Caspase-2 and
PIDD1 have also been shown to be involved in the control of
ploidy during postnatal development and regeneration in the
liver81. Two very recent papers demonstrated how the
PIDDosome may control centrosome amplification and
aneuploidy82,83. The authors found that PIDD1 is directly
recruited to mature centrosomes by the centriolar distal
appendage protein ANKRD26, and this interaction is
required for PIDDosome and caspase-2 activation following
centrosome amplification82,83. These reports suggest that
ANKRD26-dependent PIDDosome activation acts as a
centriolar signal to limit cell proliferation via the caspase-2-
p53 axis in response to centrosome amplification and
extra chromosomes.
Caspase-2 as a tumor suppressor
From the discussion above, it is apparent that caspase-2
plays an important checkpoint function by stabilizing p53
to prevent the accumulation of cells carrying damage,
thus potentially acting to suppress tumorigenesis. Indeed,
there are several lines of evidence to suggest that loss of
caspase-2 is associated with increased susceptibility to
certain types of tumors. The human CASP2 gene is in
Ch7q3484. As Ch7q is often deleted in hematological
malignancies85, reduced expression of caspase-2 (along
with other genes in this region) is not uncommon.
Reduced caspase-2 expression has been reported in some
cases of Burkitt lymphoma, mantle cell lymphoma (MCL),
chronic lymphocytic leukemia (CLL), and acute myeloid
leukemia (AML)86,87. In AML, reduced caspase-2 levels
are linked to poor prognosis88. CASP2 mutations are rare
but sometimes associated with colon, gastric lung and
breast cancer89,90. Interestingly, aneuploidy tolerance and
Fig. 4 Different physiological outcomes mediated by caspase-2-dependent p53 stabilization. A proposed scheme showing that PIDDosome-
mediated caspase-2 activation, MDM2 cleavage and p53 stabilization serves as a checkpoint under conditions of sustained DNA damage to induce
cell cycle arrest or apoptosis. The figure was created with BioRender.com.
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chromosomal instability in colon cancer correlate with
low CASP2 levels due to BCL9L gene aberrations91.
In mouse models employing caspase-2 deficiency, a
tumor suppressive effect of caspase-2 has been reported
by several laboratories (Table 1). For example, caspase-2
deficiency enhances lymphomagenesis in Eμ-Myc trans-
genic mice55,64,92 and ATM kinase-deficient animals63
and accelerates breast tumor formation in MMTV/c-neu
mice65 and in a KrasG12D-driven lung adenocarcinoma
model93. The tumor suppressor role of caspase-2 was also
apparent in a diethylnitrosamine-induced mouse hepato-
cellular carcinoma (HCC) model, where at 10 months of
age, all caspase-2-knockout animals developed malignant
HCC, whereas the WT animals showed only adenomas
and rarely HCC94. Surprisingly, a new study showed that
caspase-2 loss had no effect on diethylnitrosamine-
induced carcinogenesis95. The reason for this dis-
crepancy is unclear, but as the severity and timing of
diethylnitrosamine-induced tumor appearance is depen-
dent on many factors, the rate of HCC development may
have masked the effects of caspase-2 deficiency. On the
other hand, and interestingly, Sladky et al.95 found that
PIDDosome deficiency caused hyperpolyploidization that
prevented HCC development. In addition, caspase-2
deficiency somewhat delayed neuroblastoma develop-
ment driven by the TH-MYCN transgene in mice96.
Consistent with these findings, an analysis of expression
array datasets of primary human neuroblastoma tumor
patients demonstrated a significant correlation between
high levels of caspase-2 and poor prognosis96. Notably,
this correlation was observed in neuroblastoma patients
with nonamplified MYCN96. The tissue- and context-
specific tumor suppressor function of caspase-2 was also
apparent in the distinct transcription profiles of caspase-
2-deficient Eμ-Myc and TH-MYCN mouse tumors97.
Perspective
The work summarized here indicates that both the
PIDDosome and caspase-2 play critical roles in
p53 stabilization and cell death to prevent polyploidy,
which is required to prevent the accumulation of harmful
cells with chromosomal abnormalities. Importantly,
caspase-2 activation can also occur independent of the
PIDDosome to prevent aneuploidy and tumorigenesis.
These data suggest that caspase-2 activation serves as a
checkpoint under specific conditions of sustained cellular
or DNA damage, which may explain the tumor suppres-
sive effects of caspase-2 seen in various mouse models.
However, many questions remain. Perhaps the most
puzzling finding is that caspase-2-deficient mice acquire
only mild phenotypes and do not spontaneously develop
tumors or other specific pathologies in old age. Mice
lacking caspase-2 demonstrate increased ploidy in the
liver, and aged caspase-2 mice show increased aneuploidy
in the bone marrow compartment66. Interestingly, this
study also showed a possible role of caspase-2 in reg-
ulating hematopoietic stem cells (HSCs) and in progenitor
cell differentiation66. Caspase-2-deficient animals showed
a significant increase in short-term HSCs and multipotent
progenitors with skewed differentiation towards myeloid
progenitors with age66. Whether this phenotype repre-
sents a premyeloid state is unclear. Nevertheless, from
studies with caspase-2-deficient mouse models, it is clear
that caspase-2 deficiency is not a primary driver of
tumorigenesis. Furthermore, it has been demonstrated
that loss of caspase-2 significantly improves energy
metabolism and reduces weight gain in mice on a high-fat
diet that is associated with reduced incidence of non-
alcoholic fatty liver disease (NAFLD) progression98–100.
However, while caspase-2 has been shown to regulate
both metabolism and polyploidization in the liver81,98–100,
Table 1 Mouse tumor models used to study the effects of caspase-2 deficiency on tumourigenesis.
Mouse model Tumor Effect of caspase-2 deficiency Refs
Eµ-Myc Lymphoma Heterozygous and homozygous caspase-2 deficiency accelerated lymphoma development in
Eµ-Myc mice.
55,64,92
Atm−/− Thymoma Accelerated thymic tumor development in Atm−/− mice. 63
MMTV/c-neu Mammary tumor Homozygous caspase-2 deficiency accelerated mammary tumor formation in MMTV/c-
neu mice.
65
TH-MYCN Neuroblastoma Heterozygous and homozygous caspase-2 deficiency delayed neuroblastoma development in
TH-MYCN mice.
96
Kras Lung tumor Homozygous caspase-2 deficiency accelerated proliferation and progression of lung tumors
driven by Kras.
93
Diethylnitrosamine Hepatocellular carcinoma Accelerated hepatocellular carcinoma development. 94
Suppression of hepatocellular carcinoma development. 95
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there appear to be no dramatic consequences in normal
liver pathophysiology in caspase-2-deficient mice. Finally,
caspase-2 deficiency is linked to aging-related traits,
including increased oxidative stress and reduced levels of
antioxidant signaling101,102. These findings support the
idea that caspase-2 may play specific roles during repli-
cation stress or metabolic stress in cells. However, whe-
ther these phenotypes are acquired because of an
alteration in caspase-2-mediated p53 regulation remains
to be determined.
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